Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...

Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of pocket. The company also launched new 7.5-mg and 10-mg single-use vials, which cost $ ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...

Feb. 26 (UPI) --Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly (LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the production of key drug ingredients. Three of the four sites will produce ...

Eli Lilly said Wednesday it will invest $27 billion to build four new manufacturing plants in the United States as the pharmaceutical giant grapples with the threat of drug import duties from the ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).